The Editorial Office is pleased to answer any questions you may have about preparing your manuscript in accordance with our guidelines.
Email: liuqian@tmu.edu.cn
AIMS AND SCOPE
Blood Science is an international single blind, peer-reviewed, open access journal that publishes original research, reviews and news in the field of clinical and experimental hematology, covers the topics on molecular biology, physiology, pathophysiology and clinical applications of blood cells or non-cellular blood components. The central goal of this journal is to provide a platform for researchers to present their high impact discoveries, and to be a forum for the discussion on the important issues in the field.
Blood Science is affiliated with Chinese Association for Blood Science (CABS).
ONLINE SUBMISSION
Currently the online editorial manager submission system of the journal is under construction and will be ready soon.
Now please send the manuscripts to Kevin Liu(Email address: liuqian@tmu.edu.cn) .
JOURNAL POLICIES
DUPLICATE PUBLICATION
Manuscripts are reviewed for possible publication with the understanding that they are being submitted only to Blood Science and have not been published, simultaneously submitted, or already accepted for publication elsewhere. The Editorial team may subject any manuscript submitted for consideration of publication in Blood Science to plagiarism-detection software.
This does not preclude consideration of a manuscript that has been rejected by another journal or a complete report that follows publication of preliminary findings elsewhere, usually in the form of an abstract. Copies of any possibly duplicate published material should be submitted with the manuscript under consideration, with a statement in the cover letter as to why the manuscript currently being submitted is not a duplicate publication.
DISCLOSURE OF CONFLICTS
Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared. All sources of funding should be acknowledged in the manuscript. All relevant conflicts of interest and sources of funding should be included on the title page of the manuscript with the heading "Conflicts of Interest and Source of Funding:" For example: “Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is currently receiving a grant (#12345) from Organization Y, and is on the speaker's bureau for Organization X - the CME organizers for Company A. For the remaining authors, no relevant conflicts of interest were declared.”
AUTHORSHIP
Blood Science expects that each person listed as an author has participated sufficiently in the intellectual content, the analysis of data, and/or the writing of the manuscript to take public responsibility for it. Each author must have reviewed the manuscript, believes it represents valid work, and approves it for submission.
Moreover, should the Editorial team request the data upon which the manuscript is based, the authors shall provide the data. Each author’s specific contributions to the work should be indicated; this information will be published as a footnote to the paper. For example, the areas of participation might include:
Participated in research design
Participated in the writing of the paper
Participated in the performance of the research
Contributed new reagents or analytic tools
Participated in data analysis
An author may list more than one contribution, and more than one author may have contributed to the same aspect of the work. Any change in authorship/contributions after submission must be approved in writing by all authors and submitted to the Editorial Office for final consideration.
Reporting of Randomized Clinical Trials
Registration of Clinical Trials is an essential requirement for publication of clinical trials in Blood Science. On the title page of your manuscript, provide the name of the trial registry and the registration number/identifier of the trial.
Acceptable web-based clinical trial registries include the following:
EudraCT for EU trials
Clinical Trials for US trials
Current Controlled Trials
WHO International Trial Registry Network
Australian & New Zealand Clinical Trials Registry
And any publicly available primary registry of clinical trials
Reports of randomized clinical trials should follow the recommendations given in the Consolidated Standards of Reported Trials (CONSORT) statement. In brief, this statement comprises a checklist and flow diagram to help improve the quality of reports of randomized controlled trials and offers a standard way for researchers to report trials.
Optional Reporting Guidelines
The following resources may be helpful to authors:
PRISMA –Preferred Reporting Items for Systematic Reviews and Meta-Analyses
STROBE - Strengthening the Reporting of Observational studies in Epidemiology
STEGA - Strengthening the Reporting of Genetic Associations
Qualitative Research
Qualitative research provides in-depth insights on people’s values, attitudes, beliefs, and experiences. Qualitative methodology informs approaches to data collection and analysis, and includes grounded theory, ethnography, and phenomenology. Open-ended interviews and focus groups are commonly used to collect data. Authors are advised to follow the COREQ guidelines for reporting primary qualitative research.
Systematic review and/or synthesis of primary qualitative studies can provide a broader understanding of people’s perspectives across different healthcare contexts. Methodologies for synthesis of qualitative research include thematic synthesis, meta-ethnography and critical interpretive synthesis. Authors can refer to the ENTREQ statement.
